Navigation Links
Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Date:6/27/2011

also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission.  Except as required by law, we undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2011 Cardium Therapeutics, Inc.  All rights reserved. For Terms of Use Privacy Policy, please visit www.cardiumthx.com. Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™ and Nutra-Apps™ are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company. Ketotransdel™ and Transdel™ are trademarks of Trandsel Pharmaceutical, Inc.  (Other trademarks belong to their respective owners)


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
7. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
8. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
9. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
10. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
11. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Ambit Biosciences (Nasdaq: ... development of drugs targeting unmet needs in oncology, autoimmune and ... 2014 Health Care Conference to be held at The New ... on September 3-4, 2014. Alan Fuhrman ... and its lead drug candidate, quizartinib, at 1:10 p.m. ET ...
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... 27, 2014 Sinovac Biotech Ltd. (NASDAQ: SVA ... , today announced the results of the Company,s 2014 Annual ... Beijing , PRC. The required quorum, a majority ... The Company,s shareholders approved the following proposals:  , ... , Simon Anderson , Kenneth Lee and ...
Breaking Medicine Technology:Ambit Announces Participation At Baird 2014 Health Care Conference 2Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2
... Misonix, Inc. (NASDAQ: MSON ), a ... innovative therapeutic ultrasonic products worldwide for wound debridement, ... other surgical and medical applications, has entered into ... Solutions Australasia Pty. Ltd., based in Newport, Victoria, ...
... Aug. 12, 2011 Southern Research Institute today announced ... named Vice President of the Drug Discovery Division. Dr. ... research and target identification and lead discovery ... diseases and neurological diseases and disorders. ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Australia and New Zealand 2Misonix Announces New Distribution Agreement for Australia and New Zealand 3Southern Research Names Mark Suto Vice President of Drug Discovery 2
(Date:8/27/2014)... What’s next for 14 year old Sriram ... National Spelling Bee? Sririam will visit Philadelphia on Friday, ... Wills Eye Hospital.     , The teen from Painted Post, ... day. , Wills Eye Ophthalmologist-in-Chief, Dr. Julia Haller will ... visual diagnostic testing. He will also tour historic ...
(Date:8/27/2014)... Amy Norton HealthDay ... People who take part in clinical trials of new heart ... heart patient, a new study confirms. Experts said the ... the American Medical Association , aren,t surprising -- but they ... are enrolling a more select patient population that is not ...
(Date:8/27/2014)... August 27, 2014 Tejal K. Gandhi, MD, ... (NPSF) and the NPSF Lucian Leape Institute, is among ... August 25 issue of Modern Healthcare magazine. Also on the ... Andrew Sussman, MD, MBA; NPSF Lucian Leape Institute members ... who is a member of both the Institute and the ...
(Date:8/27/2014)... Silver Spring and Germantown, Md., and Denver (PRWEB) August ... healthcare real estate developer , has broken ground ... on the new Holy Cross Health hospital campus in ... of Bethesda, Md. Germantown is the third most populous ... medical office building on the Holy Cross Germantown Hospital ...
(Date:8/27/2014)... a parent wants to deal with, but it,s unfortunately ... old. , Skin that turns yellow can be a ... adequately eliminating the chemical bilirubin. But that discoloration is ... can harm a baby. , University of Washington engineers ... for jaundice in newborns and can deliver results to ...
Breaking Medicine News(10 mins):Health News:Scripps National Spelling Bee Co-Champion and Aspiring Ophthalmologist Coming to Wills Eye Hospital in Philadelphia 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 3Health News:NPSF President Among 100 Most Influential in Health Care 2Health News:NPSF President Among 100 Most Influential in Health Care 3Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 2Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 3Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 4Health News:New smartphone app can detect newborn jaundice in minutes 2Health News:New smartphone app can detect newborn jaundice in minutes 3
... , , , , ... Outstanding Debt to be Reduced by Approximately $54.8 Million , ... , Company to Book Approximately $8.2 Million Estimated ... by Approximately $45.4 Million , , , , ...
... ... been among the first to use NeoPlas Innovation,s new protocol. , ... Nashville, Tenn. (Vocus) June 16, 2009 -- With an ... his cancer steadily regressing on a new outpatient treatment. Individuals from 26 U.S. states and ...
... as Unwarranted, Withdraws Two Cold Remedy Nasal Products Citing Commitment ... June 16 Matrixx Initiatives, Inc. (Nasdaq: MTXX ... from the U.S. Food and Drug Administration about two of ... Gel and Zicam Cold Remedy Swabs. The warning letter cited ...
... CHICAGO, June 16 David O. Barbe, M.D., a ... the Board of Trustees of the American Medical Association. , ... , , "I am honored to be elected to the ... representing physicians as the AMA and the nation focus on health-care ...
... change" says new leader of American medicine , , ... cardiologist from Bryan, Texas, was inaugurated today as the 164th ... and most influential physician organization. , , (Logo: ... In his inaugural address as AMA president, Dr. Rohack spoke ...
... Food and Drug Administration (FDA) today advised consumers to stop ... cold remedies under the Zicam(R) brand because the use of ... of smell (a condition called anosmia ). ... zinc ingredient, The Quigley Corporation (Nasdaq: QGLY ), ...
Cached Medicine News:Health News:Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 2Health News:Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 3Health News:Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 4Health News:Inoperable Colon Cancer Responds to New Treatment 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 3Health News:AMA Inaugurates J. James Rohack as President 2Health News:Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products 2Health News:Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: